NUREXONE BIOLOGIC INC.
Research NUREXONE BIOLOGIC INC. (J90) on Bullrun: market cap EUR 39.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJ90
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 39.97M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 1.77M
- Free cash flow-USD 1.24M
Valuation Snapshot
latest market cap is EUR 39.97M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 6.38M | -USD 4.57M | n/a | n/a | USD 2.14M | USD 108.00K | USD 2.76M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 39.97M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About NUREXONE BIOLOGIC INC.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NUREXONE BIOLOGIC INC.'s market cap?
NUREXONE BIOLOGIC INC.'s market capitalization is EUR 39.97M.
What does NUREXONE BIOLOGIC INC. do?
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.